Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MT-CO2 | P00403 | 8/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | TTR | P02766 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | PLA2G1B | P04054 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolfenamic Acid SCHEMBL8060884 | 1.00 | MT-CO2 (1.00) | MT-CO2PTGS2MEN1AKR1C3KMT2A | |
| Tolfenamic Acid SCHEMBL25190 | 1.00 | MT-CO2 (1.00) | MT-CO2PTGS2MEN1AKR1C3KMT2A | |
| Tolfenamic Acid SCHEMBL29389998 | 1.00 | MT-CO2 (1.00) | MT-CO2PTGS2MEN1AKR1C3KMT2A | |
| Tolfenamic Acid SCHEMBL27540385 | 0.98 | MT-CO2 (0.97) | MT-CO2PTGS2MEN1AKR1C3KMT2A | |
| Tolfenamic Acid SCHEMBL10619715 | 0.94 | MT-CO2 (0.89) | MT-CO2PTGS2MEN1AKR1C3KMT2A | |
| Tolfenamic Acid SCHEMBL28095333 | 0.93 | MT-CO2 (0.86) | MT-CO2PTGS2MEN1AKR1C3KMT2A | |
| Tolfenamic Acid SCHEMBL28229025 | 0.90 | MT-CO2 (0.82) | MT-CO2PTGS2MEN1AKR1C3KMT2A | |
| Tolfenamic Acid SCHEMBL14976730 | 0.90 | MT-CO2 (0.82) | MT-CO2PTGS2MEN1AKR1C3KMT2A | |
| SCHEMBL11564152 | 0.88 | MT-CO2 (0.78) | MT-CO2PTGS2MEN1AKR1C3KMT2A | |
| SCHEMBL12608896 | 0.87 | MT-CO2 (0.77) | MT-CO2PTGS2MEN1AKR1C3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120081802-A | Heterocyclic substituted benzamide derivative and application thereof | 南华大学附属第一医院 | 2025-06-03 | — | — | CN | disclosed |
| CN-118986994-A | Agents and methods for modulating pathogen activity | 格里菲斯大学 | 2024-11-22 | — | — | CN | disclosed |
| CN-113164494-B | Agents and methods for modulating pathogen activity | 格里菲斯大学 | 2024-08-27 | — | — | CN | disclosed |
| CN-117355527-B | Anti-inflammatory coupling compound medicine and preparation method and application thereof | 上海椿安生物医药科技有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-117355527-A | External anti-inflammatory coupling compound medicine and preparation method and application thereof | 上海椿安生物医药科技有限公司 | 2024-01-05 | — | — | CN | disclosed |
| WO-2023001045-A9 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海椿安生物医药科技有限公司 | 2023-10-26 | — | — | WO | disclosed |
| WO-2023001045-A1 | EXTERNAL ANTI-INFLAMMATORY COUPLING COMPOUND DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海椿安生物医药科技有限公司 | 2023-01-26 | — | — | WO | disclosed |
| US-20220162171-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS | Cellix Bio Provate Limited (IN) | 2022-05-26 | — | — | US | disclosed |
| CN-110183340-B | Tofenamic acid-piperazine salt type and preparation method thereof | 天津大学 | 2022-03-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162171-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL POLYPS | APC, LPXN, SCNN1G | MT-CO2 4435/4885PTGS2 462/4885MEN1 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.